{Reference Type}: Journal Article
{Title}: Intramuscular Anti-D treatment for immune thrombocytopenia: A single centre experience.
{Author}: Lakhwani S;López-Las Heras A;Rodríguez-García P;Iraheta S;Martín-Santos T;Rodríguez-Salazar MJ;Machado P;Hernández MT;
{Journal}: Br J Haematol
{Volume}: 200
{Issue}: 3
{Year}: 02 2023
{Factor}: 8.615
{DOI}: 10.1111/bjh.18484
{Abstract}: Intravenous Anti-Rhesus-D immunoglobulin (Anti-D) is a first-line treatment option for immune thrombocytopenia in non-splenectomised and RhD-positive patients. In this report, we retrospectively review our experience with intramuscular (IM) Anti-D treatment in 74 adult patients between 1990 and 2018. We found that 73% of patients showed a response; almost all of them had complete responses (68.9%), and 26% achieved complete responses sustained at least 6 months after treatment discontinuation. [Correction added on 02 December 2022, after first online publication: In the preceding sentence, '(68.89%)' has been corrected to '(68.9%)' in this version.] No significant side effects were observed with no cases of acute haemolysis or anaemia reported. We conclude from this study that IM Anti-D is an effective and safe treatment for immune thrombocytopenia.